Michael Sen 4

Michael Sen, CEO of Fresenius
Share
Services
March 30, 2023 - April 02, 2023
Bangkok, Thailand
World Congress of Nephrology (WCN) 30.03.-02.04.2023
March 22, 2023 - March 24, 2023
Lisbon, Portugal
Congress of the European Association of Hospital Pharmacists 22.03.-24.03.2023
March 21, 2023 - March 24, 2023
Brussels, Belgium
International Symposium on Intensive Care & Emergency Medicine 21.03.-24.03.2023
Michael Sen, CEO of Fresenius
We at Fresenius are fully committed to acting with integrity and in compliance with the law. Reliability and responsibility, mutual trust and respect, fair working conditions, and a corporate culture characterized by integrity are inseparably linked to this for us, as is social and ecological sustainability. This includes respect for human rights and the protection of nature as the basis of life. Based on these values and standards, we create the necessary conditions to contribute to high-quality yet affordable healthcare. At Fresenius, the patient always comes first.
Reports on possible misconduct within our company and in our supply chain help us to live up to these standards. We follow up on these reports quickly and carefully in order to swiftly remediate violations and take measures – and to remediate grievances sustainably and effectively for the future.
Please contact us if you have evidence of misconduct or a violation of laws, policies or other regulations related to our business operations. This applies regardless of whether you are an employee – including temporary workers – or a supplier, customer, patient, resident of one of our sites or any other potentially affected party. Representatives of NGOs can also contact us with their concerns.
Reports can be submitted anonymously or by name at any time. We treat all reports confidentially and review every report carefully and comprehensively. At Fresenius, we protect all individuals who report on violations in good faith and/or support an investigation. This includes that we rigorously follow up on any cases of retaliation against such reporters. Furthermore, we investigate promptly any cases in which individuals – against their better judgement – falsely accuse others.
To make it as easy as possible for potentially affected parties, we have launched a new and improved whistleblowing system: The Fresenius Integrity Line.This is an external grievance and whistleblowing system operated by an independent provider. It can be accessed via: https://freseniusgroup.ethicspoint.com
The Fresenius Integrity Line is a comprehensive and confidential reporting platform via which you can raise any issues or concerns you may have about ethics and compliance in our workplace. We want to work with you to prevent and stop fraud, abuse, any wrongdoing that could harm our company or our patients as well as any other misconduct in the workplace while cultivating a positive work environment.
With the new Fresenius Integrity Line we offer both our own employees and external stakeholders, who have business or other relations with Fresenius, various channels to express questions or concerns. Reporting via those channels is secure, confidential, and available anytime and anywhere.
You can submit reports via the Fresenius Integrity Line online or by phone call (the phone numbers for each country are listed on the platform), anonymously or with your name. Reports can also be easily submitted using your smartphone or by scanning a QR code that we provide on the homepage of this new platform.
Information can also be sent to our functional e-mail addresses which have been set up especially for this purpose:
Reports concerning the violation of human rights can be sent to: humanrights@fresenius.com
Reports concerning any (other) Compliance violations: integrityline@fresenius.com
All other general questions to Risk & Integrity Team to: corporate-compliance@fresenius.com
Reports in writing (letters) can also be addressed to:
Fresenius SE & Co. KGaA
Business Integrity/ Group CMIO
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
Employees and temporary workers employed by Fresenius' service providers can also contact the Fresenius Group CMIO-Team by e-mail, telephone or in person. You can find the relevant contacts on the Fresenius intranet.
You can report any violations of applicable laws and Fresenius-internal regulations using the reporting channels described above. These include, e.g., corruption, competition and antitrust violations, data protection violations, violations of employee rights, as well as accounting, finance and tax violations ("compliance violations"). In addition, you can report actual or potential violations of human rights or environmental obligations related to our business activities and our direct and indirect suppliers ("human rights violations").
In your report, please describe the facts of the case as clearly and in as much detail as possible. You can use the following questions as a guide:
What? Who? When? How? Where?
If you use these questions as a guidance, we will be able to process your report more easily. If you use our web-based reporting system, after a brief information and security prompt, you will be asked to indicate the focus area of your report and to provide information on the parties involved and the time period of the violation.
It is always helpful that you are available for further queries and clarification. If you are willing to do so, but still wish to remain anonymous, please use the option of the protected mailbox available to you in our web-based reporting system.
All reports are processed by specially trained employees of our Business Integrity Team. Depending on the circumstances, it may be necessary to involve other subject matter experts and functions to further clarify an incident.
For the purpose of transparent communication, you will find below a description of the typical course of the procedure:
Fresenius commits itself and all employees involved in this process to handle all information professionally, independently and impartially, carefully and confidentially.
In accordance with the principles of fair trial, all relevant circumstances of the case will be taken into account. In addition, the principle of proportionality must always be upheld. Accused persons are presumed innocent as long as the opposite has not been proven.
Our employees involved in the various process steps are experienced in dealing professionally with reports on violations and the underlying facts. They receive ongoing training on our processes and the relevant topics. In addition, they work on incoming reports independently of instructions.
Reports on violations – and the underlying issues – can vary widely in their scope and complexity. It is therefore difficult to set a generally applicable timetable for investigations. However, we are committed to conducting and completing internal investigations as quickly and efficiently as possible.
After the conclusion of the procedure – at the latest after the expiry of three months after receipt of the report – and insofar as this does not jeopardize the investigation, you will receive a final summary and feedback on your report as well as on the measures taken, taking into account the applicable data protection regulations and other confidentiality requirements as well as safeguarding overriding company interests.
In our Fresenius Code of Conduct and our Group-wide process descriptions, we have made clear that we will not tolerate any retaliation against employees who in good faith report possible or actual violations or support investigations. This protection is also served by our measures to maintain confidentiality ('need-to-know' principle) and strict rules for dealing with conflicts of interest. In the case of external reporters, we strive to achieve a comparable level of protection and have formulated corresponding expectations in our Code of Conduct for Business Partners.
A violation of this prohibition against retaliation may be reported and investigated under the same rules as described herein.
The results of our risk analysis and the findings on potential target groups of our grievance and whistleblower channels will be incorporated into the further development of our grievance and whistleblowing procedures and the processing of grievances and whistleblowing reports. Based on our findings, we will review the effectiveness of the procedure described above on an annual basis or more frequently if required. If necessary, we will make appropriate adjustments and changes with regard to the accessibility and process of the procedure. In order to continuously improve, we also welcome suggestions and feedback from whistleblowers.
As we always strive for transparency, we regularly publish information on the number of reports received, the topics, the conclusions drawn from the reports and the measures taken. This publication is always anonymous.
* The whistleblowing system can be used for reports concerning Fresenius Management SE, Fresenius SE & Co. KGaA and Fresenius Digital Technology. Please address reports for Fresenius Kabi, Fresenius Helios or Fresenius Vamed to the relevant business segment.
Contact
Fresenius SE & Co. KGaA
Business Integrity/ Group CMIO
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Contact concerning human rights:
humanrights@fresenius.com
Contact for all other Compliance reports:
integrityline@fresenius.com
All other general Risk & Integrity topics:
corporate-compliance@fresenius.com
Whistleblowing system
Reports on possible human rights violations or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*:
Phone number: +49 (0) 800 181 1338*
https://freseniusgroup.ethicspoint.com
* The prices of your mobile or landline contract apply
Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S.
Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today.
* VIMPAT® is a registered trademark of UCB, Inc.
Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S.
Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today.
* VIMPAT® is a registered trademark of UCB, Inc.
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has entered the Dow Jones Sustainability World Index. Additionally, the company has been included for the 13th time in the Dow Jones Sustainability Index (DJSI) Europe. Fresenius Medical Care achieved an improved rating in most of the evaluated categories, and was awarded maximum scores for its environmental and social reporting. The company was also awarded significantly higher scores in the areas of occupational health and safety, talent attraction and retention, and customer relationship management.
“To us, successful sustainability management means creating lasting economic, environmental and social value,” said Helen Giza, CEO of Fresenius Medical Care. “We are proud that the DJSI has recognized our efforts to integrate sustainable actions systematically into our company.”
To compile the Dow Jones Sustainability Indexes, the international financial services company S&P Global evaluates the environmental, social and economic performance of companies. The 10 percent of global companies with the highest evaluations form the DJSI World. The DJSI Europe index is composed of the top 20 percent of the companies headquartered in Europe.
You can find an overview of Fresenius Medical Care’s progress in sustainability here.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.
In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.